close

References

• Avis NE, Crawford SL, Greendale G, et al; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539.


• Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause. 2012;19(7):749-759.


• Bromberger JT, Kravitz HM, Chang Y-F, Cyranowski JM, Brown C, Matthews KA. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychol Med. 2011;41(9):1879-1888.


• Cleveland Clinic. Hot Flashes. Reviewed March 21, 2022. Accessed March 1, 2023.  https://my.clevelandclinic.org/health/articles/15223-hot-flashes


• Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1-104.


• de Kruif M, Spijker AT, Molendijk ML. Depression during the perimenopause: a meta-analysis. J Affect Disord. 2016;206:174-180.


• Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104;(12):5893-5905.


• Endocrine Society. Menopause Signs and Symptoms. Accessed March 1, 2023. https://www.endocrine.org/menopausemap/signs-and-symptoms/index.html


• Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol. 2005;105(1):161-166.


• Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020;27(4):382-392.


• Gibson CJ, Thurston RC, Bromberger JT, Kamarck T, Matthews KA. Negative affect and vasomotor symptoms in the Study of Women's Health Across the Nation Daily Hormone Study. Menopause. 2011;18(12):1270-1277.


• Gordon JL, Peltier A, Grummisch JA, Sykes Tottenham L. Estradiol fluctuation, sensitivity to stress, and depressive symptoms in the menopause transition: a pilot study. Front Psychol. 2019;10:1319.


• Hall MH, Kline CE, Nowakowski S. Insomnia and sleep apnea in midlife women: prevalence and consequences to health and functioning. F1000Prime Rep. 2015;7:63.


• Harlow SD, Paramsothy P. Menstruation and the menopausal transition. Obstet Gynecol Clin North Am. 2011;38(3):595-607.


• Harlow SD, Gass M, Hall JE, et al; STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168.


• Heinemann LAJ, Potthoff P, Schneider HPG. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes. 2003;1:28.


• Johnson ED, Carroll DG. Venlafaxine and desvenlafaxine in the management of menopausal hot flashes. Pharm Pract (Granada). 2011;9(3):117-121.


• Kroenke K, Spitzer RL. Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.


• Kroenke K, Spitzer RL. Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292.


• Lee C-H, Giuliani F. The role of inflammation in depression and fatigue. Front Immunol. 2019;10:1696.


• Lewis CA, Kimmig ACS, Zsido RG, Jank A, Derntl B, Sacher J. Effects of hormonal contraceptives on mood: a focus on emotion recognition and reactivity, reward processing, and stress response. Curr Psychiatry Rep. 2019;21(11):115.


• Lozza-Fiacco S, Gordon JL, Andersen EH, et al. Baseline anxiety-sensitivity to estradiol fluctuations predicts anxiety symptom response to transdermal estradiol treatment in perimenopausal women - a randomized clinical trial. Psychoneuroendocrinology. 2022;143:105851.


• Maki PM, Kornstein SG, Joffe H, et al; Board of Trustees for The North American Menopause Society (NAMS) and the Women and Mood Disorders Task Force of the National Network of Depression Centers. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018;25(10):1069-1085.


• Mann E, Smith M, Hellier J, Hunter MS. A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): trial protocol. BMC Cancer. 2011;11:44.


• “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.


• Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155-1174.


• North American Menopause Society. Menopause Practice: A Clinician’s Guide, 6^th ed. NAMS; 2019.


• North American Menopause Society. Menopause 101: A Primer for the Perimenopausal. Accessed March 1, 2023.https://www.menopause.org/for-women/menopauseflashes/menopause-symptoms-and-treatments/menopause-101-a-primer-for-the-perimenopausal


• North American Menopause Society. Menopause Glossary. Accessed March 1, 2023.  https://www.menopause.org/for-women/menopause-glossary


• North American Menopause Society. How Do I Know When I'm in Menopause? Accessed March 1, 2023.   https://www.menopause.org/for-women/menopauseflashes/menopause-symptoms-and-treatments/how-do-i-know-when-i'm-in-menopause-


• Office on Women’s Health. Early or premature menopause. Last updated December 29, 2022. Accessed March 1, 2023. https://www.womenshealth.gov/menopause/early-or-premature-menopause


• Parel NS, Krishna PV, Gupta A, et al. Depression and vitamin d: a peculiar relationship. Cureus. 2022;14(4):e24363.


• Pearce EN. Thyroid dysfunction in perimenopausal and postmenopausal women. Menopause Int. 2007;13(1):8-13.


• Pinkerton JV, Joffe H, Kazempour K, Mekonnen H, Bhaskar S, Lippman J. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause. Menopause. 2015;22(1):50-58.


• Reddy SY, Warner H, Guttuso Jr T, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol. 2006;108(1):41-48.


• Sangle P, Sandhu O, Aftab Z, Anthony AT, Khan S. Vitamin B12 supplementation: preventing onset and improving prognosis of depression. Cureus. 2020;12(10):e11169.


• Santoro N, Waldbaum A, Lederman S, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020;27(12):1350-1356.


• Santoro N. Perimenopause: from research to practice. J Womens Health (Larchmt). 2016;25(4):332-339.


• Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2014;29(1):204-213.


• Shifren J, Gass MLS; NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038-1062.


• Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013;20(10):1027-1035.


• Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.